Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Lexicon Pharmaceuticals to related businesses based on the strength of its valuation, dividends, risk, analyst recommendations, institutional ownership, earnings and profitability.
Valuation & Earnings
This table compares Lexicon Pharmaceuticals and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Lexicon Pharmaceuticals | $49.80 million | -$50.34 million | -12.50 |
| Lexicon Pharmaceuticals Competitors | $715.39 million | $10.31 million | -18.32 |
Lexicon Pharmaceuticals’ rivals have higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Analyst Recommendations
This is a summary of recent ratings and target prices for Lexicon Pharmaceuticals and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lexicon Pharmaceuticals | 1 | 1 | 3 | 0 | 2.40 |
| Lexicon Pharmaceuticals Competitors | 9931 | 15323 | 45708 | 1605 | 2.54 |
Lexicon Pharmaceuticals currently has a consensus price target of $5.80, suggesting a potential upside of 231.43%. As a group, “Biotechnology” companies have a potential upside of 131.48%. Given Lexicon Pharmaceuticals’ higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than its rivals.
Volatility & Risk
Lexicon Pharmaceuticals has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals’ rivals have a beta of -1.84, indicating that their average share price is 284% less volatile than the S&P 500.
Institutional & Insider Ownership
74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Lexicon Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lexicon Pharmaceuticals | -161.80% | -35.76% | -24.53% |
| Lexicon Pharmaceuticals Competitors | -12,319.70% | -407.93% | -30.95% |
Summary
Lexicon Pharmaceuticals beats its rivals on 8 of the 13 factors compared.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals is a biopharmaceutical company based in The Woodlands, Texas. Founded in 1995 as Lexicon Genetics, the company uses drug discovery and development research to create medicines for serious diseases, with a focus on areas of unmet medical need. Its commercial product, Inpefa (sotagliflozin), is approved in the United States to reduce the risk of cardiovascular death and worsening heart failure in adults with heart failure. Lexicon also develops investigational medicines, including candidates studied for neuropathic pain and other conditions.
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
